ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Dr Hope Rugo speaks to ecancer about her talks at BGICC 2021. She says that this year she talked about sequencing endocrine treatment in metastatic luminal breast cancer. She also talks about the use of alpelisib in treatment of metastatic breast cancer.
In this talk, she reviews luminal breast cancer and what is seen in terms of intrinsic sub typing in metastatic breast cancer by comparing early stage diseases. She also says that to date we don’t have any predictive biomarkers to test this disease.
She then moves on to explain some studies like the MONALISA study which reviewed different drug combinations and their efficacies.
Dr Rugo mentions the data from several other studies and highlights what it means for the patient in terms of clinical outcomes. In the end, she talks about alpelisib and its use in treating metastatic breast cancer.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
OncoAlert Round Up for August 25th - 31st, 2023
Loco-regional management after neoadjuvant chemotherapy